Related Experiment Video

Updated: Jun 15, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Statin treatment for patients with heart failure

W H Wilson Tang1, Gary S Francis

  • 1Department of Cardiovascular Medicine, Cleveland Clinic Heart and Vascular Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA. tangw@ccf.org

Nature Reviews. Cardiology
|March 18, 2010
PubMed

Insights

Statins show potential for preventing heart failure, especially in those with coronary artery disease. However, current evidence suggests limited benefit for chronic heart failure survival, indicating a need for careful timing of statin therapy.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Statins are widely used for cardiovascular disease prevention.
  • Observational studies suggest potential benefits of statins in heart failure (HF).
  • Conflicting results exist regarding statin efficacy in HF patients.

Purpose of the Study:

  • To review current evidence on statin use in heart failure.
  • To evaluate the safety and efficacy of statins in HF patients.
  • To discuss implications for statin therapy initiation in HF.

Main Methods:

  • Analysis of observational studies.
  • Review of post hoc analyses of cardiovascular databases.
  • Examination of data from large, prospective, controlled trials (e.g., rosuvastatin trials).

Main Results:

  • Statins may halt HF disease progression, particularly in patients with coronary artery disease.
  • Two large trials showed neutral effects of rosuvastatin on chronic HF survival.
  • Potential benefits may be limited to HF prevention or new-onset HF.

Conclusions:

  • Statin therapy might be more beneficial for preventing heart failure than treating established chronic HF.
  • The timing of statin initiation is crucial for potential efficacy in HF patients.
  • Further research may clarify the role of statins in specific HF populations.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...